Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-04-30

FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for SELARSDI (ustekinumab-aekn) from Teva Pharmaceuticals USA, Inc., representing an approval of a biosimilar product to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SELARSDI (USTEKINUMAB-AEKN)

Snippet

SUPPL AP for SELARSDI (USTEKINUMAB-AEKN)